Smallpox – Variola
Smallpox is one of the deadliest acute infectious diseases in human history. It is caused by variola virus, a large double-stranded DNA virus of the genus Orthopoxvirus, family Poxviridae. The disease is marked by severe whole-body viral toxicity and a deep pustular rash with a distinctive centrifugal pattern, concentrated on the face and limbs. Although the World Health Organization (WHO) declared smallpox eradicated worldwide in 1980 after a mass vaccination campaign, understanding how variola virus causes disease and what it looks like clinically remains essential for biosecurity and for differential diagnosis in modern dermatology.
Like other members of the Poxviridae family, variola virus replicates entirely within the cytoplasm of the host cell. It drives proliferation and then necrosis of epidermal cells, producing umbilicated pustules that extend down into the dermis. Widespread destruction of the basement membrane and dermal papillae at the height of the illness is what leaves survivors with deep, lifelong atrophic pitted scars (pockmarks).
At Haute-Derma, understanding the pattern of poxvirus skin damage helps us screen for and accurately distinguish smallpox from re-emerging acute pustular illnesses such as mpox or severe chickenpox. It also shapes our advanced skin-resurfacing programs. By combining fractional CO2 laser, long-pulsed 1064 nm Nd:YAG laser and scar subcision, we help rebuild collagen and fill in the deep, distorting atrophic scars that poxvirus infections can leave behind.
Pathogenesis and Clinical Forms of Variola Virus
Entry and Spread Through the Bloodstream
- Route of entry: variola virus spreads mainly through the airways, by inhaling respiratory droplets, or by direct contact with fluid from an infected person's skin lesions.
- Two waves of viremia: the virus enters the upper airway lining, multiplies in regional lymph nodes and causes a primary viremia. It then seeds the reticuloendothelial organs (liver, spleen, bone marrow), where it multiplies explosively, leading to a severe secondary viremia that carries virus to the small-vessel endothelium of the dermal papillae and mucous membranes.
Clinical Forms
- Variola major: the classic form, with an extensive rash, severe systemic toxicity and a death rate of up to 30%. It has 4 main clinical types:
- Ordinary: more than 85% of cases; lesions pass through every stage.
- Confluent: pustules merge into large sheets on the face and forearms; the outlook is very poor.
- Flat (malignant): soft, flat lesions that never become raised pustules; mortality is extremely high.
- Hemorrhagic (purpura variolosa): widespread bleeding into the skin and mucous membranes from the prodromal stage, rapidly fatal from shock and multiorgan failure.
- Variola minor (alastrim): a much milder form with sparse skin lesions, gentler systemic symptoms and a death rate below 1%.
Clinical Features
Prodromal phase: lasts 2 to 4 days. Patients develop a sudden high fever of 39.0–40.5°C with shaking chills, intense headache, severe lower back pain, exhaustion and agitation, sometimes with abdominal pain and vomiting.
Rash (exanthem) phase and centrifugal distribution:
- Mucosal onset (enanthem): the first lesions are shallow ulcers on the tongue, palate and throat, which shed large amounts of virus into the saliva.
- Centrifugal skin rash: the rash starts on the face, then quickly spreads to the forearms, lower legs, palms and soles. It is always far denser on the face and extremities than on the trunk (chest and abdomen).
- Synchronous evolution: the key clinical hallmark. All lesions in a given body area move through each stage at the same time:
- Days 1–2: small red macules quickly become firm papules that feel like peas under the skin.
- Days 3–4: papules turn into vesicles filled with clear fluid.
- Days 5–8: vesicles become deep, round, well-defined pustules with a distinct central dimple (umbilication).
- Days 9–14: pustules dry out and form firm, gray-black crusts that stick tightly to the skin.
- Day 15 onward: crusts fall off, leaving pale patches and deep atrophic pitted scars (pockmarks).
Diagnosis and Biosafety at Haute-Derma
Clinical examination and rash assessment: we look for the centrifugal distribution of the rash, deep-seated pustules and lesions that are all at the same stage within each body area.
Dermoscopy:
- Umbilicated pustules surrounded by a deep red rim.
- Central necrosis of the dermal papillae, without the fine crown-like vessels seen in molluscum contagiosum.
Biosafety and laboratory testing: if a dangerous orthopoxvirus infection is suspected, the clinic immediately activates biosafety isolation procedures, notifies the public health authorities and collects samples (pustule fluid or crusts) for real-time PCR or electron microscopy (EM) at a high-containment laboratory.
Management and Skin Recovery at Haute-Derma
Acute Treatment and Antiviral Drugs
- Specific antivirals:
- Tecovirimat (TPOXX): blocks the poxvirus p37 protein, stopping the virus from leaving infected cells. Dose: 600 mg by mouth twice daily for 14 days.
- Brincidofovir: a lipid-conjugated form of cidofovir that inhibits viral DNA polymerase.
- Local care and prevention of secondary infection:
- Clean the lesions with octenidine dihydrochloride or nanosilver solution twice a day.
- Avoid rough handling or early crust removal, to limit how deep the scars become.
Treating Smallpox Scars (Pockmarks) at Haute-Derma
Smallpox scars are deep atrophic scars (icepick or deep boxcar) caused by complete breakdown of collagen and elastin fibers in the dermis. Our layered treatment plan includes:
- Subcision: a specialized medical needle releases the stiff fibrous bands that tether the base of the scar to the subcutaneous tissue.
- Fractional CO2 laser resurfacing: creates precise microthermal zones that stimulate fibroblasts to make new type I and III collagen, filling in the scar.
- Growth factor mesotherapy and PLLA: poly-L-lactic acid (PLLA) or platelet-rich plasma (PRP) is injected directly into the scar base to help the depressions fill in faster.
